Abstract:Objective: Insulin resistance is a critical factor contributing to the pathogenesis of type 2 diabetes and other metabolic diseases. Recent studies have indicated that miR-338-3p plays an important role in cancer. Here, we investigated whether miR-338-3p mediates tumour necrosis factor-α (TNF-α)-induced hepatic insulin resistance. Methods: The activation of the insulin signalling pathway and the level of glycogenesis were examined in the livers of the db/db and high fat diet (HFD)-fed mice and in HEP1-6 cells transfected with miR-338-3p mimic or inhibitor. Computational prediction of microRNA target, luciferase assay and Western blot were used to assess the miR-338-3p target. Chromatin immunoprecipitation (ChIP) assay was used to determine the transcriptional regulator of miR-338-3p. Results: miR-338-3p was down-regulated in the livers of the db/db, HFD-fed and TNF-α-treated C57BL/6J mice, as well as in mouse HEP1-6 hepatocytes treated with TNF-α. Importantly the down-regulation of miR-338-3p induced insulin resistance, as indicated by impaired glucose tolerance and insulin tolerance. Further research showed that the down-regulated miR-338-3p resulted in the impaired AKT/ glycogen synthase kinase 3 beta (GSl·Gβ) signalling pathway and glycogen synthesis. In contrast, hepatic over-expression of miR-338-3p rescued the TNF-α-induced insulin resistance. Moreover, protein phosphatase 4 regulator subunit 1 (PP4R1) was identified as a direct target of miR-338-3p that mediated hepatic insulin signalling by regulating protein phosphatase 4 (PP4). Finally we identified hepatic nuclear factor 4 alpha (HNF-4α) as the transcriptional regulator of miRNA-338-3p. Conclusions: Our studies provide novel insight into the critical role and molecular mechanism by which miR-338-3p is involved in TNF-α-induced hepatic insulin resistance. miR-338-3p might mediate TNF-α-induced hepatic insulin resistance by targeting PP4R1 to regulate PP4 expression.

Down-Regulation of the Mir-543 Alleviates Insulin Resistance Through Targeting the Sirt1

Downregulation of Mir-181A Upregulates Sirtuin-1 (SIRT1) and Improves Hepatic Insulin Sensitivity

[Mir-494-3p Reduces Insulin Sensitivity in Diabetic Cardiomyocytes by Down-Regulation of Insulin Receptor Substrate 1].

MiR-155-5p Promotes Renal Interstitial Fibrosis in Obstructive Nephropathy Via Inhibiting SIRT1 Signaling Pathway

Circulating Mir-143-3p Inhibition Protects Against Insulin Resistance in Metabolic Syndrome Via Targeting of the Insulin-Like Growth Factor 2 Receptor.

Mir-338-3p Mediates Tnf-A-Induced Hepatic Insulin Resistance by Targeting Pp4r1 to Regulate Pp4 Expression

Inhibition of miR-543 alleviates cardiac fibroblast-to-myofibroblast transformation and collagen expression in insulin resistance via targeting PTEN

Mir-140-5p Aggravates Insulin Resistance Via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.

Upregulation of Mir-181A Impairs Hepatic Glucose and Lipid Homeostasis.

MiR-377 Promotes White Adipose Tissue Inflammation and Decreases Insulin Sensitivity in Obesity Via Suppression of Sirtuin-1 (SIRT1)

Inhibition Of Mirna-135a-5p Ameliorates Tgf-Beta 1-Induced Human Renal Fibrosis By Targeting Sirt1 In Diabetic Nephropathy

miR‐221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin‐1 (SIRT1)

SIRT1 Attenuates High Glucose-Induced Insulin Resistance Via Reducing Mitochondrial Dysfunction in Skeletal Muscle Cells.

Inhibition of miRNA-155 Alleviates High Glucose-Induced Podocyte Inflammation by Targeting SIRT1 in Diabetic Mice

Targeting Mir128-3P Alleviates Myocardial Insulin Resistance and Prevents Ischemia-Induced Heart Failure

Mir-150 Regulates Glucose Utilization Through Targeting GLUT4 in Insulin-Resistant Cardiomyocytes

Down-regulation of Risa Improves Insulin Sensitivity by Enhancing Autophagy.

Sirt3 Pharmacologically Promotes Insulin Sensitivity through PI3/AKT/mTOR and Their Downstream Pathway in Adipocytes

MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction

Inhibition of P53/miR‐34a Improves Diabetic Endothelial Dysfunction Via Activation of SIRT1

Berberine Potentiates Insulin Secretion and Prevents β-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway